Role of oxidative stress mediated by glutathione-s-transferase in thiopurines' toxic effects.
Study Design
- Study Type
- Other
- Population
- IBD patients
- Intervention
- Role of oxidative stress mediated by glutathione-s-transferase in thiopurines' toxic effects. 1 g
- Comparator
- standard therapy
- Primary Outcome
- None
- Effect Direction
- Positive
- Risk of Bias
- Unclear
Abstract
Azathioprine (AZA), 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG) are antimetabolite drugs, widely used as immunosuppressants and anticancer agents. Despite their proven efficacy, a high incidence of toxic effects in patients during standard-dose therapy is recorded. The aim of this study is to explain, from a mechanistic point of view, the clinical evidence showing a significant role of glutathione-S-transferase (GST)-M1 genotype on AZA toxicity in inflammatory bowel disease patients. To this aim, the human nontumor IHH and HCEC cell lines were chosen as predictive models of the hepatic and intestinal tissues, respectively. AZA, but not 6-MP and 6-TG, induced a concentration-dependent superoxide anion production that seemed dependent on GSH depletion. N-Acetylcysteine reduced the AZA antiproliferative effect in both cell lines, and GST-M1 overexpression increased both superoxide anion production and cytotoxicity, especially in transfected HCEC cells. In this study, an in vitro model to study thiopurines' metabolism has been set up and helped us to demonstrate, for the first time, a clear role of GST-M1 in modulating AZA cytotoxicity, with a close dependency on superoxide anion production. These results provide the molecular basis to shed light on the clinical evidence suggesting a role of GST-M1 genotype in influencing the toxic effects of AZA treatment.
TL;DR
An in vitro model to study thiopurines' metabolism has been set up and helped to demonstrate, for the first time, a clear role of GST-M1 in modulating AZA cytotoxicity, with a close dependency on superoxide anion production.
Used In Evidence Reviews
Similar Papers
Digestion · 2016
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.
Gut · 1996
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
Journal of nanobiotechnology · 2022
Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy.
Frontiers in endocrinology · 2024
The emerging role of oxidative stress in inflammatory bowel disease.
The British journal of nutrition · 2012
Omega-3 fatty acids and inflammatory bowel diseases - a systematic review.
Helicobacter · 2007